Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial) : Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial

Malm, Carl Johan ; Alfredsson, Joakim ; Erlinge, David LU orcid ; Gudbjartsson, Tomas ; Gunn, Jarmo ; James, Stefan ; Møller, Christian H. ; Nielsen, Susanne J. ; Sartipy, Ulrik and Tønnessen, Theis , et al. (2023) In American Heart Journal 259. p.1-8
Abstract

The TACSI trial (ClinicalTrials.gov Identifier: NCT03560310) tests the hypothesis that 1-year treatment with dual antiplatelet therapy with acetylsalicylic acid (ASA) and ticagrelor is superior to only ASA after isolated coronary artery bypass grafting (CABG) in patients with acute coronary syndrome. The TACSI trial is an investor-initiated pragmatic, prospective, multinational, multicenter, open-label, registry-based randomized trial with 1:1 randomization to dual antiplatelet therapy with ASA and ticagrelor or ASA only, in patients undergoing first isolated CABG, with a planned enrollment of 2200 patients at Nordic cardiac surgery centers. The primary efficacy end point is a composite of time to all-cause death, myocardial infarction,... (More)

The TACSI trial (ClinicalTrials.gov Identifier: NCT03560310) tests the hypothesis that 1-year treatment with dual antiplatelet therapy with acetylsalicylic acid (ASA) and ticagrelor is superior to only ASA after isolated coronary artery bypass grafting (CABG) in patients with acute coronary syndrome. The TACSI trial is an investor-initiated pragmatic, prospective, multinational, multicenter, open-label, registry-based randomized trial with 1:1 randomization to dual antiplatelet therapy with ASA and ticagrelor or ASA only, in patients undergoing first isolated CABG, with a planned enrollment of 2200 patients at Nordic cardiac surgery centers. The primary efficacy end point is a composite of time to all-cause death, myocardial infarction, stroke, or new coronary revascularization within 12 months after randomization. The primary safety end point is time to hospitalization due to major bleeding. Secondary efficacy end points include time to the individual components of the primary end point, cardiovascular death, and rehospitalization due to cardiovascular causes. High-quality health care registries are used to assess primary and secondary end points. The patients will be followed for 10 years. The TACSI trial will give important information useful for guiding the antiplatelet strategy in acute coronary syndrome patients treated with CABG.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
American Heart Journal
volume
259
pages
8 pages
publisher
Mosby-Elsevier
external identifiers
  • scopus:85147579647
  • pmid:36681173
ISSN
0002-8703
DOI
10.1016/j.ahj.2023.01.011
language
English
LU publication?
yes
id
4283b6df-e665-4e75-a421-2d8d0da01f2e
date added to LUP
2023-03-10 11:50:40
date last changed
2024-06-13 20:17:53
@article{4283b6df-e665-4e75-a421-2d8d0da01f2e,
  abstract     = {{<p>The TACSI trial (ClinicalTrials.gov Identifier: NCT03560310) tests the hypothesis that 1-year treatment with dual antiplatelet therapy with acetylsalicylic acid (ASA) and ticagrelor is superior to only ASA after isolated coronary artery bypass grafting (CABG) in patients with acute coronary syndrome. The TACSI trial is an investor-initiated pragmatic, prospective, multinational, multicenter, open-label, registry-based randomized trial with 1:1 randomization to dual antiplatelet therapy with ASA and ticagrelor or ASA only, in patients undergoing first isolated CABG, with a planned enrollment of 2200 patients at Nordic cardiac surgery centers. The primary efficacy end point is a composite of time to all-cause death, myocardial infarction, stroke, or new coronary revascularization within 12 months after randomization. The primary safety end point is time to hospitalization due to major bleeding. Secondary efficacy end points include time to the individual components of the primary end point, cardiovascular death, and rehospitalization due to cardiovascular causes. High-quality health care registries are used to assess primary and secondary end points. The patients will be followed for 10 years. The TACSI trial will give important information useful for guiding the antiplatelet strategy in acute coronary syndrome patients treated with CABG.</p>}},
  author       = {{Malm, Carl Johan and Alfredsson, Joakim and Erlinge, David and Gudbjartsson, Tomas and Gunn, Jarmo and James, Stefan and Møller, Christian H. and Nielsen, Susanne J. and Sartipy, Ulrik and Tønnessen, Theis and Jeppsson, Anders}},
  issn         = {{0002-8703}},
  language     = {{eng}},
  pages        = {{1--8}},
  publisher    = {{Mosby-Elsevier}},
  series       = {{American Heart Journal}},
  title        = {{Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial) : Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial}},
  url          = {{http://dx.doi.org/10.1016/j.ahj.2023.01.011}},
  doi          = {{10.1016/j.ahj.2023.01.011}},
  volume       = {{259}},
  year         = {{2023}},
}